Clinical Trials Directory

Trials / Conditions / Plexiform Neurofibromas

Plexiform Neurofibromas

11 registered clinical trials studyying Plexiform Neurofibromas — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingNeurofibromatosis Type 1 Tumor Early Detection Study
NCT06515860
David Miller—
WithdrawnSelumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Stud
NCT05825365
AstraZenecaPhase 2
RecruitingHL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
NCT05331105
Shanghai Kechow Pharma, Inc.Phase 2
TerminatedUS Selumetinib Registry
NCT05683678
Alexion Pharmaceuticals, Inc.—
CompletedTargeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach
NCT02777775
Corewell Health West—
RecruitingDevelopment and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1
NCT02544022
National Cancer Institute (NCI)—
CompletedAcceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform N
NCT02471339
National Cancer Institute (NCI)Phase 3
TerminatedStudy of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
NCT02177825
St. Justine's HospitalPhase 2
CompletedCabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
NCT02101736
University of Alabama at BirminghamPhase 2
TerminatedStudy of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
NCT01402817
Indiana UniversityPhase 2
CompletedStudy of Plexiform Neurofibromas in Neurofibromatosis Type 1
NCT00006435
National Cancer Institute (NCI)—